ELISA Complement Activity Analysis

Product name

Ba MicroVue™ Quidel®

Quantification of the Complement Ba fragment

Cat-Nr.A034
Range0.05 – 2.1 ng/ml
SensitivityLOD: 0.011 ng/ml; LLOQ: 0.033 ng/ml
Incubation time3 hours
Sample volume10 µl (dilute plasma 1:1000, serum 1:2000), 25 µl urine (dilute 1:15)
Sample type

EDTA Plasma, serum, urine

Sample preparation

Serum / Plasma:
The Ba fragment of Factor B is susceptible to proteolysis. For optimal plasma results, K2 EDTA should be used. Collect blood sample and centrifuge immediately at 2-8°C. Assay immediately, do not store longer than 2 hours at 2-8°C. For longer storage -70°C.
Urine:
Collect preservative-free first Morning void (FMV) or second morning void (SMV) before 10:00 am. Store sample refrigerated (2-8°C) for less than
1 day, or freeze the sample at -70°C for longer storage.
Maximum 5 freeze and thaw cycles.

Reference values
Sample    n     Mean  Range (ng/ml)
EDTA Plasma 35 658 226-2153
Serum 29 1642 436-3362
Urine 16 7.7 0.6-27.0

 

Species

Human, African green monkey, cynomolgus monkey, rhesus monkey,
canine

Specificity

Monoclonal mouse-antibody, specifically to capture the Ba fragment.

Tests96
MethodELISA
Intended use

By quantifying the amount of Ba, the extent of alternative pathway activation at the time of sample collection can be determined.

Activation of the alternative pathway has been associated with a variety of disease states including SLE, chronic glomerulonephritis, rheumatoid arthritis, sickle cell anemia and gram negative bacterial infections.

The activation of the alternative complement pathway can be triggered by a variety of substances including microbial polysaccharides or lipids, gram-negative bacterial lipopolysaccharides, surface determinants present on some viruses, parasites, virally infected mammalian cells, and cancer cells. In autoimmune
diseases, the alternative complement pathway may contribute directly to tissue damage. Alternative complement pathway activation may also be an indicator of hemo-incompatibility of biomaterials.

  • kidney diseases
    chronic glomerulonephritis
    lupus nephritis
  • skin diseases
    dermatitis herpetiformis
    pemphigus vulgaris
  • age-related macular degeneration
  • fetal loss in at risk pregnancy
  • rheumatoid arthritis
  • sickle cell anemia
     
Product informations

Back to overview